The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 30, 2024
Filed:
Mar. 24, 2021
Applicant:
Academia Sinica, Taipei, TW;
Inventors:
Assignee:
ACADEMIA SINICA, Taipei, TW;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12P 21/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); C07K 16/283 (2013.01); C12P 21/005 (2013.01); C12Y 302/01 (2013.01); C12Y 302/01051 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.